Enterprise Value
-14.81M
Cash
29.73M
Avg Qtr Burn
-4.204M
Short % of Float
0.38%
Insider Ownership
0.55%
Institutional Own.
6.81%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rigosertib + Pembrolizumab Details Melanoma, Skin cancer, Cancer | Phase 2 Data readout | |
Rigosertib (RAS inhibitor) Details Cutaneous squamous cell carcinoma, Solid tumor/s, Cancer | Phase 2 Update | |
Rigosertib + Nivolumab Details Non-small cell lung carcinoma, Cancer | Phase 1/2 Data readout | |
Narazaciclib + letrozole Details Solid tumor/s, Cancer, Endometrial cancer | Phase 1/2 Data readout | |
Narazaciclib (ON 123300) (CDK4/6 & ARK5 inhibitor) Details Solid tumor/s, Cancer, Breast cancer, ER+/HER2- breast cancer, Metastatic breast cancer | Phase 1 Data readout | |
Rigosertib Details Myelodysplastic syndrome | Failed Discontinued |